Kiniksa Pharmaceuticals International, plc
KNSA
$76.75
-$1.08-1.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 243.60M | 214.27M | 202.13M | 180.86M | 156.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 243.60M | 214.27M | 202.13M | 180.86M | 156.80M |
| Cost of Revenue | 111.64M | 96.37M | 90.98M | 83.56M | 71.02M |
| Gross Profit | 131.96M | 117.89M | 111.15M | 97.29M | 85.78M |
| SG&A Expenses | 63.87M | 61.15M | 56.78M | 49.10M | 46.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 216.41M | 185.00M | 182.36M | 156.83M | 136.64M |
| Operating Income | 27.19M | 29.27M | 19.77M | 24.02M | 20.16M |
| Income Before Tax | 31.15M | 32.68M | 23.27M | 27.16M | 22.88M |
| Income Tax Expenses | 5.71M | 10.09M | 9.07M | 8.72M | 5.05M |
| Earnings from Continuing Operations | 25.43M | 22.59M | 14.20M | 18.44M | 17.83M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.43M | 22.59M | 14.20M | 18.44M | 17.83M |
| EBIT | 27.19M | 29.27M | 19.77M | 24.02M | 20.16M |
| EBITDA | 27.67M | 29.74M | 20.24M | 24.41M | 20.52M |
| EPS Basic | 0.33 | 0.30 | 0.19 | 0.25 | 0.24 |
| Normalized Basic EPS | 0.25 | 0.27 | 0.19 | 0.23 | 0.19 |
| EPS Diluted | 0.30 | 0.27 | 0.18 | 0.23 | 0.23 |
| Normalized Diluted EPS | 0.23 | 0.25 | 0.18 | 0.21 | 0.18 |
| Average Basic Shares Outstanding | 77.58M | 76.52M | 75.97M | 74.71M | 73.44M |
| Average Diluted Shares Outstanding | 83.40M | 82.41M | 81.57M | 80.04M | 77.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |